Search

01/12/2022 A Response to: Letter to the Editor Regarding Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis
Armstrong, AW, Soliman, AM, Betts, KA, Wang, Y, Gao, YW, Stakias, V, Puig, L. A Response to: Letter to the Editor Regarding Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis. Dermatology and Therapy. 2022; 12(12)DOI:10.1007/s13555-022-00812-z. PMID:36271222. IF:3.400(Q2/3D).
01/11/2022 Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO)
Pinter, A, Puig, L, Schakel, K, Reich, A, Zaheri, S, Costanzo, A, Tsai, TF, Smith, SD, Lynde, C, Brnabic, A, Reed, C, Hill, J, Schuster, C, Riedl, E, Paul, C. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO). JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(11)DOI:10.1111/jdv.18376. PMID:35766124. IF:9.200(Q1/1D).
01/11/2022 SEB-induced IL-13 production in CLA(+) memory T cells defines Th2 high and Th2 low responders in atopic dermatitis
Sans-De San Nicolas, L, Figueras-Nart, I, Bonfill-Orti, M, De Jesus-Gil, C, Garcia-Jimenez, I, Guilabert, A, Curto-Barredo, L, Bertolin-Colilla, M, Ferran, M, Serra-Baldrich, E, Zalewska-Janowska, A, Wang, YH, Howell, MD, Pujol, RM, Santamaria-Babi, LF. SEB-induced IL-13 production in CLA(+) memory T cells defines Th2 high and Th2 low responders in atopic dermatitis. ALLERGY. 2022; 77(11)DOI:10.1111/all.15424. PMID:35773619. IF:12.400(Q1/1D).
01/11/2022 Deucravacitinib for the Treatment of Psoriatic Disease
Le, AM, Puig, L, Torres, T. Deucravacitinib for the Treatment of Psoriatic Disease. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2022; 23(6)DOI:10.1007/s40257-022-00720-0. PMID:35960487. IF:7.300(Q1/1D).
01/11/2022 Drug Survival of Interleukin (IL)-17 and IL-23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi-country, Multicentric Cohort Study
Torres, T, Puig, L, Vender, R, Yeung, J, Carrascosa, JM, Piaserico, S, Gisondi, P, Lynde, C, Ferreira, P, Bastos, PM, Dauden, E, Leite, L, Valerio, J, del Alcazar-Viladomiu, E, Rull, EV, Llamas-Velasco, M, Pirro, F, Messina, F, Bruni, M, Licata, G, Ricceri, F, Nidegger, A, Hugo, J, Mufti, A, Daponte, AI, Teixeira, L, Balato, A, Romanelli, M, Prignano, F, Gkalpakiotis, S, Conrad, C, Lazaridou, E, Rompoti, N, Papoutsaki, M, Nogueira, M, Chiricozzi, A. Drug Survival of Interleukin (IL)-17 and IL-23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi-country, Multicentric Cohort Study. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2022; 23(6)DOI:10.1007/s40257-022-00722-y. PMID:35976568. IF:7.300(Q1/1D).
01/11/2022 European guideline (EuroGuiDerm) on atopic eczema - part II: non-systemic treatments and treatment recommendations for special AE patient populations
Wollenberg, A, Kinberger, M, Arents, B, Aszodi, N, Valle, GA, Barbarot, S, Bieber, T, Brough, HA, Pinton, PC, Christen-Zach, S, Deleuran, M, Dittmann, M, Dressler, C, Fink-Wagner, AH, Fosse, N, Gaspar, K, Gerbens, L, Gieler, U, Girolomoni, G, Gregoriou, S, Mortz, CG, Nast, A, Nygaard, U, Redding, M, Rehbinder, EM, Ring, J, Rossi, M, Serra-Baldrich, E, Simon, D, Szalai, ZZ, Szepietowski, JC, Torrelo, A, Werfel, T, Flohr, C. European guideline (EuroGuiDerm) on atopic eczema - part II: non-systemic treatments and treatment recommendations for special AE patient populations. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(11)DOI:10.1111/jdv.18429. PMID:36056736. IF:9.200(Q1/1D).